Background: Microbiota-based treatments are effective in preventing recurrent Clostridioides difficile infection (rCDI). Fecal microbiota, live-jslm (REBYOTA®; RBL, previously RBX2660) was shown to prevent rCDI in a phase 3, randomized, double-blinded placebo controlled clinical trial (PUNCH™ CD3).
Methods: Stool samples from participants in PUNCH™ CD3 who received a single blinded dose of rectally administered RBL or placebo were sequenced to determine microbial community composition and calculate the Microbiome Health Index for post-antibiotic dysbiosis (MHI-A).
Microbiome-based therapeutics are increasingly evaluated as a strategy to reduce recurrent infection (rCDI), with proposed mechanisms including restoration of the microbiota and microbiota-mediated functions, such as bile acid (BA) metabolism. This study reports a quantitative and sensitive assay for targeted metabolomic assessment, and the application of the assay to profile BA composition in a Phase 2 trial of the investigational microbiota-based live biotherapeutic RBX2660 for reduction of rCDI. A liquid chromatography tandem mass spectrometry method was developed to extract and quantify 35 BAs from 113 participant stool samples from 27 RBX2660-treated rCDI participants in the double-blinded, placebo-controlled clinical trial.
View Article and Find Full Text PDFWe propose a multi-qubit Bose-Einstein-condensate (BEC) trap as a platform for studies of quantum statistical phenomena in many-body interacting systems. In particular, it could facilitate testing atomic boson sampling of the excited-state occupations and its quantum advantage over classical computing in a full, controllable and clear way. Contrary to a linear interferometer enabling Gaussian boson sampling of non-interacting non-equilibrium photons, the BEC trap platform pertains to an interacting equilibrium many-body system of atoms.
View Article and Find Full Text PDF